NCT01612351 2026-03-17
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
21 trialsNCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT03358472 2025-12-03
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
Phase 3 Completed
NCT02358031 2025-07-18
MK-3475-048
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01437449 2024-01-30
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Stanford University
Phase 2 Completed
NCT02741570 2023-09-21
CheckMate 651
Bristol-Myers Squibb
Phase 3 Completed
NCT00089297 2023-06-29
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02578641 2023-06-28
VANCE
Tessa Therapeutics
Phase 3 Completed
NCT01716195 2021-02-26
Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer
University of California, Davis
Phase 2 Completed
NCT01412229 2020-11-23
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02124707 2020-08-12
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01063075 2019-09-26
A Study in Advanced Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT00343083 2019-08-19
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)
University of Maryland, Baltimore
Phase 2 Completed
NCT01016769 2019-06-26
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02633800 2019-01-07
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
Daiichi Sankyo
Phase 2 Terminated
NCT01009346 2018-07-17
RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Terminated
NCT00270790 2017-02-01
EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202)
University of Maryland, Baltimore
Phase 2 Completed
NCT00580983 2016-09-07
Optimized Intensity Modulated Irradiation for Head and Neck Cancer
University of Michigan Rogel Cancer Center
Phase NA Completed
NCT01283334 2014-12-04
A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer
Emory University
Phase 1/2 Completed
NCT00581971 2013-04-25
RAD0201
University of Alabama at Birmingham
Phase 1/2 Completed
NCT00301028 2013-04-05
Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer
M.D. Anderson Cancer Center
Phase 2 Completed